The immune system’s role in conception and implantation is one of the most complex and clinically relevant frontiers in reproductive medicine. A successful pregnancy requires the maternal immune system to tolerate a semi-foreign embryo — a delicate immunological negotiation that can fail in multiple ways, some of which directly affect ICI outcomes and recurrent early pregnancy loss.
Anti-Sperm Antibodies and ICI
Anti-sperm antibodies (ASA) are immunoglobulins that bind to sperm surface antigens and impair sperm function. ASA can be present in either the male (binding sperm in the reproductive tract) or the female (produced against a partner’s sperm antigens), and both types are associated with reduced fertility. In women, cervical mucus is the primary site of ASA-mediated sperm damage — antibodies in cervical secretions can immobilize sperm or prevent penetration of cervical mucus, directly impeding the sperm transit that ICI depends upon. ASA testing is indicated in cases of unexplained infertility, particularly when post-coital testing (PCT) or IUI sperm analysis reveals poor mucus penetration despite normal semen parameters.
The prevalence of clinically significant ASA in infertile women is approximately 5–15%, making it a relevant but not dominant cause of ICI failure. In male partners, ASA is found in 5–10% of infertile men and is associated with agglutination and impaired motility in semen analysis. For ICI, ASA-mediated cervical mucus impairment is particularly relevant — it is one of the specific cases where upgrading from ICI (which deposits sperm near the cervix where ASA-rich mucus is present) to IUI (which bypasses the cervical mucus entirely) produces a meaningful improvement in pregnancy rates. ASA testing is available through reproductive immunology laboratories and should be considered after two to three unexplained ICI failures.
Uterine NK Cells and Implantation
Natural killer (NK) cells in the endometrium — termed uterine NK cells (uNK) — play paradoxical roles in implantation: they are essential for normal trophoblast invasion and placentation, but elevated uNK cell activity has been associated with recurrent implantation failure and early pregnancy loss in some studies. The debate around peripheral blood NK cell testing (CD56+CD16- cells) as a predictor of uNK activity and implantation failure has been ongoing for over a decade, with significant controversy among reproductive immunologists.
Current ASRM and RCOG position statements do not support routine NK cell testing for women with recurrent implantation failure due to insufficient evidence that peripheral blood NK cell levels accurately reflect uterine NK activity, or that treating elevated peripheral NK cell counts improves IVF or ICI outcomes. Investigational treatments including intravenous immunoglobulin (IVIG), intralipid infusions, and prednisolone have been used in reproductive immunology centers for patients with high peripheral NK cells and recurrent failure, but evidence from randomized trials is insufficient to recommend these as standard care. For ICI patients with otherwise unexplained recurrent failure, a reproductive immunology consultation is appropriate to discuss what testing is evidence-supported versus investigational.
Antiphospholipid Syndrome
Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by the presence of antiphospholipid antibodies (aPL) — including lupus anticoagulant (LA), anticardiolipin antibodies (aCL), and anti-beta2 glycoprotein I (anti-β2GPI) — associated with thrombosis and/or pregnancy complications. In the context of fertility, APS is one of the most well-established immunological causes of recurrent pregnancy loss, accounting for approximately 15–20% of cases. The mechanism involves placental microthrombi that impair placental blood flow and spiral artery remodeling in early pregnancy.
For ICI users with a history of unexplained recurrent early pregnancy loss (three or more losses before 10 weeks), testing for aPL antibodies is recommended in ASRM guidelines. Positive aPL testing requires confirmation on two separate tests at least 12 weeks apart to distinguish persistent from transient positivity. For ICI candidates with confirmed APS, treatment during a conception cycle and early pregnancy with low-dose aspirin (81 mg daily starting before ovulation) and low-molecular-weight heparin (LMWH, beginning at confirmed pregnancy) has demonstrated significantly improved live birth rates in randomized trials. This treatment protocol is the standard of care for APS-associated recurrent loss and should be implemented under hematology and obstetric medicine co-management.
Thyroid Autoimmunity and ICI Outcomes
Thyroid autoimmunity — the presence of anti-thyroid peroxidase (anti-TPO) or anti-thyroglobulin (anti-TG) antibodies — is the most prevalent immune disorder in reproductive-age women, affecting 8–14%. Even in women who are euthyroid (normal TSH), thyroid antibody positivity is independently associated with reduced IVF implantation rates, increased miscarriage risk, and potentially reduced ICI success. The mechanism is not fully understood but may involve direct endometrial effects of thyroid antibodies, subclinical thyroid dysfunction below standard TSH diagnostic thresholds, or broader immune dysregulation associated with thyroid autoimmunity.
Testing for anti-TPO antibodies before beginning ICI cycles is not yet standard universal screening, but ASRM recommends it for women with a history of recurrent pregnancy loss or unexplained infertility. For ICI candidates over 30 with irregular cycles, family history of autoimmune disease, or any history of miscarriage, thyroid antibody testing adds meaningful diagnostic information at low cost. For euthyroid women with positive antibodies, evidence does not firmly establish that levothyroxine treatment improves outcomes — a large randomized trial (T4Life) is ongoing — but many reproductive endocrinologists treat when TSH is above 2.5 mIU/L in conjunction with antibody positivity, as the benefit-to-risk ratio of low-dose levothyroxine is favorable.
For a complete at-home insemination solution, the His Fertility Boost includes everything you need for a properly timed, sterile ICI cycle. For a complete at-home insemination solution, the MakeAmom Babymaker Kit includes everything you need for a properly timed, sterile ICI cycle.
Further reading across our network: IntracervicalInsemination.org · MakeAmom.com
This article is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making decisions about your fertility care.
